WallStSmart

AbbVie Inc (ABBV)vsWW International, Inc. Common Stock (WW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 8506% more annual revenue ($61.16B vs $710.64M). WW leads profitability with a 148.6% profit margin vs 6.9%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.7Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

WW

Buy

56

out of 100

Grade: C

Growth: 4.7Profit: 5.5Value: 5.7Quality: 6.5
Piotroski: 4/9Altman Z: 12.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-29.3%)

Margin of Safety

-29.3%

Fair Value

$163.42

Current Price

$203.89

$40.47 premium

UndervaluedFair: $163.42Overvalued

Intrinsic value data unavailable for WW.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$360.63B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4810/10

Growing faster than its price suggests

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
34.1%10/10

Strong operational efficiency at 34.1%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

WW5 strengths · Avg: 10.0/10
P/E RatioValuation
1.3x10/10

Attractively priced relative to earnings

Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Profit MarginProfitability
148.6%10/10

Keeps 149 of every $100 in revenue as profit

EPS GrowthGrowth
5268.0%10/10

Earnings expanding 5268.0% YoY

Altman Z-ScoreHealth
12.9910/10

Safe zone — low bankruptcy risk

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
6.9%3/10

6.9% margin — thin

P/E RatioValuation
100.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-88.7%2/10

Earnings declined 88.7%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

WW4 concerns · Avg: 2.8/10
Market CapQuality
$97.97M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Debt/EquityHealth
1.453/10

Elevated debt levels

PEG RatioValuation
4.922/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.

Bull Case : WW

The strongest argument for WW centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 148.6% and operating margin at -5.4%.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.

Bear Case : WW

The primary concerns for WW are Market Cap, Return on Equity, Debt/Equity.

Key Dynamics to Monitor

ABBV profiles as a value stock while WW is a declining play — different risk/reward profiles.

WW carries more volatility with a beta of 1.06 — expect wider price swings.

ABBV is growing revenue faster at 10.0% — sustainability is the question.

ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (63/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

WW International, Inc. Common Stock

HEALTHCARE · MEDICAL CARE FACILITIES · USA

WW International, Inc. offers worldwide weight management products and services. The company is headquartered in New York, New York.

Visit Website →

Want to dig deeper into these stocks?